Showing results (71-80 of 206) with videos related to
Sort By:
Pageof 21
United European Gastroenterology Journal|March 12, 2025
Diagnosis and Monitoring Pathways Using Non-Invasive Tests in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease: Results From an Expert Delphi PanelVirginia C Clark, Mark A Price, Jon Russo, et al.Plos One|July 14, 2012
Hsp72 overexpression accelerates the recovery from caerulein-induced pancreatitisMariia Lunova, Eugen Zizer, Ozlem Kucukoglu, et al.BMC Gastroenterology|October 20, 2012
Keratin 8 variants are infrequent in patients with alcohol-related liver cirrhosis and do not associate with development of hepatocellular carcinomaValentyn Usachov, Pierre Nahon, Mariia Lunova, et al.The Journal of Biological Chemistry|February 5, 2005
Human Ran cysteine 112 oxidation by pervanadate regulates its binding to keratinsGuo-Zhong Tao, Qin Zhou, Pavel Strnad, et al.Plos One|March 28, 2008
Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injuryMatthew Siegel, Pavel Strnad, R Edward Watts, et al.Plos One|March 14, 2012
Non-coding keratin variants associate with liver fibrosis progression in patients with hemochromatosisPavel Strnad, Ozlem Kucukoglu, Mariia Lunova, et al.Digestive Diseases and Sciences|June 8, 2012
Diagnosis of hereditary hemochromatosis in the era of genetic testingChristiane Trieß, Guido von Figura, Manfred Stuhrmann, et al.World Journal of Gastrointestinal Oncology|December 2, 2021
Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancerKatharina Joechle, Jessica Guenzle, Claus Hellerbrand, et al.Gastroenterology|April 6, 2007
Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargementPavel Strnad, Masaru Harada, Matthew Siegel, et al.FEBS Letters|April 18, 2006
Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formationPavel Strnad, Matthew Siegel, Diana M Toivola, et al.Pageof 21